Heritage medicine
About · Heritage

Sixty Years of Medicine,
Reframed for Regenerative Care.

Established in 1964, Medical Corporation Yamamoto Iin has served community medicine for three generations. On that foundation, Cellforce One Clinic Tokyo now delivers the next era of medicine — regenerative, preventive, personalized — from the heart of Ginza.

Philosophy

Your body. Your responsibility.

Japan's super-aged society has reached a turning point in medical economics. Rather than waiting for insurance coverage to catch up, we believe in the proactive protection of one's own body through three layers: prevention, early intervention, and regeneration. Our integrated care experience unites precision imaging, cellular therapy, and concierge coordination under one philosophy.

Heritage / Timeline

From 1964 to the Present.

1964 · Shōwa 39

Yamamoto Iin Founded

In the year of the Tokyo Olympic Games — as Japan transitioned from post-war reconstruction to high-growth modernization — Yamamoto Iin was established as a community medical practice. Three generations of medical succession begin here.

2014

Act on Safety of Regenerative Medicine Enacted

Japan became the first country in the world to establish a comprehensive legal framework for regenerative medicine (Act No. 85 of 2013, effective 2014). Regulatory infrastructure for clinic-level cellular therapy delivery was formally established.

2020s

Cellforce One Clinic Tokyo Launched

Cellforce One Clinic Tokyo (CFO) opens in Ginza. Built on the medical legacy of Yamamoto Iin, the clinic integrates regenerative therapy, preventive care, and precision imaging, with dedicated inbound patient capability.

2025

CMEF Shanghai · International Stage

Presented at the 91st China International Medical Equipment Fair (CMEF 2025) and the Medical AI Innovation Forum. CFO began global thought-leadership on precision regenerative medicine.

2026 · Today

Cell-Processing Governance Established

The clinic organizes filed regenerative-medicine provision plans, cell-processing and operational contracts, physician review, informed consent, quality confirmation, and periodic reporting.

Certifications & Registrations

Medicine backed by
science and regulation.

01

Regenerative Medicine Provider · Class II

Filed / notified under Japan's Act on Safety of Regenerative Medicine (Act No. 85 of 2013). The clinic manages MSC chronic pain plans (PB3240161 / PB3250154) and MSC osteoarthritis plans (PB3240166 / PB3250155), with physician review before any treatment decision.

02

Regenerative Medicine Provider · Class III

NK cell therapy is filed / notified as a Category III regenerative-medicine provision plan (Plan No. PB3250244), reviewed by the Certified Committee on Regenerative Medicine (General Incorporated Association · Cellular Immunology Research Society).

03

Specialist Referral When Needed

When specialist or higher-level care is necessary, the clinic considers referral or external medical consultation according to the patient's condition and urgency.

04

Japanese Society for Regenerative Medicine

Membership in Japan's leading academic society for regenerative medicine. Practice is informed by current scientific consensus and peer-reviewed clinical evidence.

Cell Processing Governance

Cell processing and quality checks,
managed by provision plan.

The clinic manages filed provision plans, cell-processing and operational contracts, informed-consent flow, quality confirmation, and reporting obligations. Details are reviewed by the physician for each patient.

01 · Processing

Cell Processing Review

For each provision plan, the clinic confirms cell-processing facility, quality checks, transport and storage conditions, and treatment schedule.

02 · Consent

Informed Consent

Self-pay status, cost, main risks, alternatives, and suitability are explained by the physician before any procedure is considered.

03 · Reporting

Reporting and Filing Management

The clinic manages five provision plans and six related contracts, with annual / periodic reporting and necessary filing management.

Leadership

Representative Director
& Managing Physician.

Director

Dr. Tatsuro Ichimaru, MD

Representative Director and Managing Physician of Cellforce One Clinic Tokyo. As the regulatory responsible officer for both Class II and Class III regenerative medicine delivery plans, Dr. Ichimaru oversees clinical operations, cellular therapy protocols, and safety governance across the clinic's full practice scope.

Governance

Medical Corporation Yamamoto Iin maintains a board of directors and a statutory auditor under the representative director. A certified tax accountant and a licensed attorney serve as standing directors, establishing a robust governance structure that spans clinical, executive, financial, and legal oversight — ensuring integrated governance across medical practice, business operations, and compliance.

Location

Central Ginza,
directly opposite Ginza Six.

Cellforce One Clinic Tokyo
Medical Corporation Yamamoto Iin

〒104-0061
Kikusui Diana Building 5F-B
6-9-6 Ginza, Chuo-ku, Tokyo, Japan

TEL: +81-3-6228-5751
support@cellforceoneclinic.com

Hours: Mon–Fri 10:00 – 17:00 JST · By appointment only

Tokyo Metro — Ginza Line · Marunouchi Line · Hibiya Line

Ginza Station, Exit A3 — approx. 5 min walk

Tokyo Metro · Toei Asakusa Line

Higashi-Ginza Station, Exit A1 — approx. 3 min walk

Landmark

Directly across from Ginza Six, on Chuo-dōri.

Get in Touch

Sixty years of heritage,
carried into the next generation.

Inquiries, appointments, and Medical Stay Visa coordination for international patients — we are happy to assist.